Aptinyx Inc.

aptinyx.com

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. The company is headquartered in Evanston, Illinois and currently employs 12 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The firm focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The firm's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The firm's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.